BiotechTube

HRF2105 patch + Loxoprofen patch + placebo

Phase 2UNKNOWN
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Analgesia and Anti-inflammatory of Osteoarthritis

Conditions

Analgesia and Anti-inflammatory of Osteoarthritis

Trial Timeline

Oct 1, 2023 → Dec 1, 2023

NCT ID
NCT06047483

About HRF2105 patch + Loxoprofen patch + placebo

HRF2105 patch + Loxoprofen patch + placebo is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Analgesia and Anti-inflammatory of Osteoarthritis. The current trial status is unknown. This product is registered under clinical trial identifier NCT06047483. Target conditions include Analgesia and Anti-inflammatory of Osteoarthritis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT06047483Phase 2UNKNOWN

Competing Products

20 competing products in Analgesia and Anti-inflammatory of Osteoarthritis

See all competitors
ProductCompanyStageHype Score
AcetaminophenJohnson & JohnsonPhase 2
52
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparationJiangsu Hengrui MedicinePhase 1
33
Bupivacaine Liposome InjectionJiangsu Hengrui MedicineApproved
85
Paracetamol injection + Normal Saline injection + Morhpine PCAJiangsu Hengrui MedicinePhase 2/3
65
Bupivacaine Liposome Injection + Bupivacaine Hydrochloride InjectionJiangsu Hengrui MedicinePhase 2
52
Org 28611 + morphine sulfate + PlaceboMerckPhase 2
52
oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + marketed oxycodone hydrochloridePfizerPhase 1
32
Ibuprofen 600 mg Immediate Release/Extended Release CapletPfizerPhase 3
76
HSK21542 Injection + Tramadol hydrochloride + placeboHaisco Pharmaceutical GroupPhase 3
74
Experimental: stage I：HSK21542 0.4 μg/kg + Experimental: stage I：HSK21542 1 μg/kg + Experimental: stage I：HSK21542 0.5μg/kg + Experimental: stage I：HSK21542 1μg/kg + Experimental: stage II：HSK21542 0.5μg/kg + Experimental: stage II：HSK21542 1μg/kg + PlaceboHaisco Pharmaceutical GroupPhase 2
49
Stage I: HSK21542 0.5 μg/kg + Stage I: HSK21542 1 μg/kg + HSK21542 0.5 μg/kg + HSK21542 1 μg/kg + HSK21542 2 μg/kg + PlaceboHaisco Pharmaceutical GroupPhase 2
49
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
74
HTX-011 + Ibuprofen + Acetaminophen + Celecoxib + +/- Bupivacaine HCl + HTX-011Heron TherapeuticsPhase 3
69
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenHeron TherapeuticsApproved
77
HTX-011 + HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsPhase 2
44
Bupivacaine HClHeron TherapeuticsApproved
77
HTX-011 + PlaceboHeron TherapeuticsPhase 2
44
HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsPhase 3
69
Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusionHeron TherapeuticsApproved
77
HTX-011 + Bupivacaine HCl + HTX-011 + HTX-011 + HTX-011Heron TherapeuticsPhase 2
44

Other Products from Jiangsu Hengrui Medicine

ApatinibApproved
85
Remimazolam TosilateApproved
85
Henagliflozin 10 mg daily + Metformin 1700 mg dailyApproved
85
ImrecoxibApproved
85
IvarmacitinibApproved
85